◎I・バンク氏を最高財務責任者に指名 パレクセル・インターナショナル
◎I・バンク氏を最高財務責任者に指名 パレクセル・インターナショナル
AsiaNet 53396
共同JBN 0705 (2013.6.14)
【ボストン2013年6月14日PRN=共同JBN】有力な世界的バイオ医薬品サービス会社であるパレクセル・インターナショナル(PAREXEL International Corporation、http://www.parexel.com/;ナスダック:PRXL)は14日、このほどインゴ・バンク(Ingo Bank)氏が同社上級副社長に指名され、年度末監査済み財務報告書提出後の9月1日付で最高財務責任者(CFO)に就任すると発表した。バンク氏は7月8日、ロイヤル・フィリップス(Royal Philips)からパレクセルに入社する。同氏はロイヤル・フィリップスのCFO、フィリプス・ヘルスケアの執行副社長を務めていた。バンク氏は米マサチューセッツ州ウォルサムのパレクセル本社に駐在する。
バンク氏は現CFOのジェームズ・F・ウィンチェル氏の後任。ウィンチェル氏は9月1日まで上級副社長兼CFOとしてとどまり、その後は2014年の退社まで執行副社長に就く。ウィンチェル氏はスムーズなCFO引き継ぎとパレクセルの収益向上に注力する。パレクセルは2012年8月にウィンチェル氏の退社を発表している。
パレクセル・インターナショナルのジョセフ・フォン・リッケンバック会長兼最高経営責任者(CEO)は「パレクセルは世界的経験を備えたリーダーを歓迎する。彼は、さまざまな業界分野にまたがった財務管理で素晴らしい経歴を持っている。われわれが成長戦略を推進し、株主に利益の出る結果を提供し続けるため努力している時期にあたり、バンク氏の事業への洞察力、改善と業績へのたゆまぬ集中力は大いに役立つだろう」と語った。
バンク氏はパレクセル・インターナショナル入社以前、ロイヤル・フィリップスに18年間勤務し、同社ではさまざまな世界的財務担当上級職を務めた。彼はロイヤル・フィリプスの内部監査執行役員で、日本と中国におけるフィリプスのLCD事業の構築と変革をCFOに任命され、合併・吸収を管理し、フィリップスのグローバルな照明ランプ事業のCFOを務めた。バンク氏はまた、フィリプス・ヘルスケアの執行副社長兼CFOとして、アナリスト向けイベントでの説明役を務め投資家と交流した。
CFO就任についてバンク氏は「医薬品開発業務受託機関(CRO、http://www.paraxel.com/)のリーダーであるパレクセルに入社でき大変うれしい。わたしは傑出した財務チームに加わり、収益を伴うパレクセルの成長に寄与したいと考えている」と述べた。
バンク氏はドイツ出身で、ドイツのヴィッテン・ヘァデッケ大学で経営学修士号を、オランダのアムステルダム・マーストリヒト大学でレジスタード・コントローラー(Registered Controller)の資格を取得した。
リッケンバック会長兼CEOは「インゴ・バンク氏をパレクセルに歓迎するにあたり、同じようにグローバルな財務管理に対するウィンチェル氏のこれまでのコミットメントを多としたい。パレクセルの市場資本化は、ウィンチェル氏の下で2億2500万ドルから27億ドルに成長した。役務収益は3億7800万ドルから17億ドルに増加し、バックログは3億8500万ドルから40億ドル超になった。ウィンチェル氏に感謝するとともに、引き続き当社にとどまってくれることに感謝する」と述べた。
▽パレクセル・インターナショナル(PAREXEL International Corporation)について
パレクセル・インターナショナルは世界的大手バイオ医薬品会社として、広い領域で知識ベースの委託研究((http://www.parexel.com/clinical-research-services)、コンサルティング、医療コミュニケーション・サービスを世界の医薬品、バイオテクノロジー、医療機器業界に提供している。市場進出時間、ピーク・マーケット・ペネトレーションを促進するソリューションの提供にコミットしているパレクセルは、医薬品開発と規制コンサルティングから臨床薬理学、臨床試験管理、医療教育、償還に至る開発と商業化の連続体全体にわたって重要な専門知識を身につけている。パレクセルの子会社であるPerceptive Infomatics, Inc.は、医療画像を含む先進的な技術ソリューションを提供して臨床開発プロセスを容易にしている。米マサチューセッツ州ボストン近くに本社を置くパレクセルは、世界52カ国の78カ所で活動しており、従業員は約1万4400人。パレクセル・インターナショナルについての詳しい情報はhttp://www.parexel.comを参照。
PAREXELはPAREXEL International Corporationの登録商標、Perceptive InfomaticsはPerceptive Infomatics, Inc.の登録商標。ほかのすべての名称、マークはPAREXEL International Corporation、Perceptive Infomatics, Inc.あるいはそれぞれの所有者の登録商標または商標であり、ここに通告する。
▽問い合わせ先
Jill Baker
Corporate Vice President
Investor Relations
Tel: +1-781-434-4118
Email: Jill.Baker@PAREXEL.com;
Diana Martin
Vice President
Corporate Communications
PAREXEL International
Tel: +1-781-434-5516
Email: Diana.Martin@PAREXEL.com
ソース:PAREXEL International Corporation
PAREXEL International Appoints Ingo Bank as Senior Vice President and Chief Financial Officer
PR53396
BOSTON, June 14, 2013 /PRN=KYOD JBN/ --
- Industry veteran brings 18 years of global finance, operations, and
strategic corporate development experience to PAREXEL
PAREXEL International Corporation (http://www.parexel.com/) (NASDAQ:
PRXL), a leading global biopharmaceutical services provider, today announced
that Ingo Bank has been appointed Senior Vice President and will become Chief
Financial Officer on September 1, after fiscal year-end audited financial
statements are filed. He joins PAREXEL on July 8 from Royal Philips, where he
served as Chief Financial Officer and Executive Vice President of Philips
Healthcare. Mr. Bank will be based at the Company's corporate headquarters in
Waltham, Massachusetts.
Mr. Bank succeeds outgoing CFO James F. Winschel, Jr., who will remain at
PAREXEL as Senior Vice President and Chief Financial Officer until September 1,
after which he will serve as Executive Vice President until he retires in
2014. Mr. Winschel will focus on ensuring a smooth transition and improving
the Company's profitability. PAREXEL announced Mr. Winschel's retirement in
August 2012.
"PAREXEL is pleased to welcome a leader with Ingo's global experience. He
has an impressive record overseeing financial management across a variety of
industry sectors. Ingo's business acumen and focus on continuous improvement
and performance will serve us well as we drive our growth strategy and focus on
continuing to deliver profitable results to our stakeholders," said Josef von
Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.
Before joining PAREXEL International, Mr. Bank spent 18 years with Royal
Philips, holding numerous senior global finance positions. He was the Chief
Audit Executive of Royal Philips, was appointed into CFO roles to build and
transform the LCD business for Philips in Japan and China, managed mergers and
acquisitions, and served as CFO of the global Philips Lamps business. As EVP
and CFO of Philips Healthcare, Mr. Bank also was a speaker at analyst events
and interacted with investors.
On his new appointment, Mr. Bank said, "I am excited to join PAREXEL, a
leader in the CRO (http://www.parexel.com/) industry. I join an exceptional
management team and look forward to contributing to the Company's profitable
growth."
Mr. Bank is a native of Germany, holds a Master's of Business
Administration from the University Witten-Herdecke, Germany, and is a
Registered Controller from University Amsterdam/Maastricht, The Netherlands.
"As we welcome Ingo Bank to PAREXEL, I would also like to recognize Jim's
commitment to overseeing the worldwide financial management for the Company.
Under his leadership, PAREXEL's market capitalization grew from $225 million to
$2.7 billion, service revenue increased from $378 million to $1.7 billion and
backlog grew from $385 million to over $4 billion," said Mr. von Rickenbach.
He added, "We thank Jim for his efforts and his continued involvement in the
Company."
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical
services organization, providing a broad range of knowledge-based contract
research (http://www.parexel.com/clinical-research-services), consulting, and
medical communications services to the worldwide pharmaceutical, biotechnology
and medical device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed significant
expertise across the development and commercialization continuum, from drug
development and regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. Perceptive Informatics, Inc.,
a subsidiary of PAREXEL, provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process. Headquartered
near Boston, Massachusetts, PAREXEL operates in 78 locations throughout 52
countries around the world, and has approximately 14,400 employees. For more
information about PAREXEL International visit http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results
and events. For this purpose, any statements contained herein that are not
statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements in this
release involve a number of risks and uncertainties. The Company's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Important factors that
might cause such a difference include, but are not limited to, risks associated
with: actual operating performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings; the loss,
modification, or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog; the Company's
dependence on certain industries and clients; the Company's ability to win new
business, manage growth and costs, and attract and retain employees; the
Company's ability to complete additional acquisitions and to integrate newly
acquired businesses or enter into new lines of business; the impact on the
Company's business of government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical industry and
competition within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of exchange rate fluctuations and
other international economic, political, and other risks. Such factors and
others are discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31,
2013 as filed with the SEC on May 6, 2013, which "Risk Factors" discussion is
incorporated by reference in this press release. The Company specifically
disclaims any obligation to update these forward-looking statements in the
future. These forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date subsequent to the
date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and
Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other
names or marks may be registered trademarks or trademarks of PAREXEL
International Corporation, Perceptive Informatics, Inc. or their respective
owners and are hereby acknowledged.
CONTACTS: Jill Baker
Corporate Vice President
Investor Relations
Tel: +1-781-434-4118
Email: Jill.Baker@PAREXEL.com;
Diana Martin
Vice President
Corporate Communications
PAREXEL International
Tel: +1-781-434-5516
Email: Diana.Martin@PAREXEL.com
SOURCE: PAREXEL International Corporation
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。